

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5713154

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JANSSEN-CILAG	03/31/2019
RECEIVING PARTY DATA	
Name:	JANSSEN PHARMACEUTICALS, INC.
Street Address:	1125 TRENTON-HARBOURTON ROAD
City:	TITUSVILLE
State/Country:	NEW JERSEY
Postal Code:	08560
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16492667
CORRESPONDENCE DATA	
Fax Number:	(212)336-8001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212 336 8000
Email:	ptodocket@arelaw.com
Correspondent Name:	AMSTER ROTHSTEIN & EBENSTEIN LLP
Address Line 1:	90 PARK AVENUE
Address Line 4:	NEW YORK, NEW YORK 10016
ATTORNEY DOCKET NUMBER:	29248/261
NAME OF SUBMITTER:	ALAN D. MILLER
SIGNATURE:	/Alan D. Miller/
DATE SIGNED:	09/11/2019
Total Attachments: 1 source=assign#page1.tif	

General Assignment

WHEREAS, Janssen-Cilag having its place of business at 1 rue Camille Desmoulins, TSA 91003, 92787 Issy-les-Moulineaux Cedex 9, France (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS"

for which on the 31st day of March 2017, European Patent Application no. 17164045.1 was filed at the European Patent Office.

WHEREAS, Janssen Pharmaceuticals, Inc., having its place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560, USA (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof.

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 31st day of March 2017.


IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen-Cilag



.....
Luc Quaghebeur, Authorized Signatory
For Janssen-Cilag

For Janssen Pharmaceuticals, Inc.



.....
Frank Daelemans, Authorized Signatory
For Janssen Pharmaceuticals, Inc.